Tango Other Stockholder Equity from 2010 to 2024

TNGX Stock  USD 3.10  0.16  5.44%   
Tango Therapeutics Other Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Other Stockholder Equity will likely drop to about 395.6 M in 2024. During the period from 2010 to 2024, Tango Therapeutics Other Stockholder Equity regression line of annual values had r-squared of  0.62 and arithmetic mean of  148,256,141. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2010-12-31
Previous Quarter
624.1 M
Current Value
395.6 M
Quarterly Volatility
234 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tango Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tango Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 3.6 M or Selling General Administrative of 22.1 M, as well as many indicators such as Price To Sales Ratio of 19.37, Dividend Yield of 0.0 or PTB Ratio of 6.45. Tango financial statements analysis is a perfect complement when working with Tango Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tango Therapeutics Correlation against competitors.
For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.

Latest Tango Therapeutics' Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Tango Therapeutics over the last few years. It is Tango Therapeutics' Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tango Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Tango Other Stockholder Equity Regression Statistics

Arithmetic Mean148,256,141
Geometric Mean16,258,760
Coefficient Of Variation157.82
Mean Deviation194,141,807
Median3,311,000
Standard Deviation233,972,462
Sample Variance54743.1T
Range620.8M
R-Value0.78
Mean Square Error22645.7T
R-Squared0.62
Significance0.0005
Slope41,057,885
Total Sum of Squares766403.6T

Tango Other Stockholder Equity History

2024395.6 M
2023624.1 M
2022522.6 M
2021506.8 M
2020141.6 M

About Tango Therapeutics Financial Statements

Tango Therapeutics investors use historical fundamental indicators, such as Tango Therapeutics' Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tango Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity624.1 M395.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.